NOVAVAX INC (NVAX)

US6700024010 - Common Stock

7.1  -0.01 (-0.14%)

Fundamental Rating

1

NVAX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 612 industry peers in the Biotechnology industry. Both the profitability and financial health of NVAX have multiple concerns. While showing a medium growth rate, NVAX is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year NVAX has reported negative net income.
In the past year NVAX has reported a negative cash flow from operations.
NVAX had negative earnings in each of the past 5 years.
NVAX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

NVAX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NVAX has a Gross Margin of 55.82%. This is in the better half of the industry: NVAX outperforms 79.14% of its industry peers.
The Profit Margin and Operating Margin are not available for NVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM N/A
GM 55.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVAX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NVAX has been increased compared to 5 years ago.
Compared to 1 year ago, NVAX has a worse debt to assets ratio.

2.2 Solvency

NVAX has an Altman-Z score of -4.17. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVAX (-4.17) is worse than 63.74% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.17
ROIC/WACCN/A
WACC8.3%

2.3 Liquidity

NVAX has a Current Ratio of 0.71. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
NVAX has a Current ratio of 0.71. This is amonst the worse of the industry: NVAX underperforms 94.21% of its industry peers.
A Quick Ratio of 0.69 indicates that NVAX may have some problems paying its short term obligations.
With a Quick ratio value of 0.69, NVAX is not doing good in the industry: 93.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.69

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.69% over the past year.
Looking at the last year, NVAX shows a very strong growth in Revenue. The Revenue has grown by 23.74%.
NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.40% yearly.
EPS 1Y62.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q108.88%
Revenue growth 1Y23.74%
Revenue growth 3Y373.24%
Revenue growth 5Y129.4%
Revenue growth Q2Q128.28%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.34% on average per year.
The Revenue is expected to decrease by -5.29% on average over the next years.
EPS Next Y81.64%
EPS Next 2Y37.7%
EPS Next 3Y23.93%
EPS Next 5Y17.34%
Revenue Next Year-32.08%
Revenue Next 2Y-19.78%
Revenue Next 3Y-17.86%
Revenue Next 5Y-5.29%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVAX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NVAX's earnings are expected to grow with 23.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.7%
EPS Next 3Y23.93%

0

5. Dividend

5.1 Amount

NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NOVAVAX INC

NASDAQ:NVAX (9/27/2023, 1:27:01 PM)

7.1

-0.01 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-06 2023-11-06/amc
Inst Owners60.96%
Inst Owner Change-4.25%
Ins Owners0.32%
Ins Owner Change10.44%
Market Cap670.27M
Analysts75
Price Target21.01 (195.92%)
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.22%
Min EPS beat(2)3.43%
Max EPS beat(2)141.01%
EPS beat(4)2
Avg EPS beat(4)-58.23%
Min EPS beat(4)-234.4%
Max EPS beat(4)141.01%
Revenue beat(2)2
Avg Revenue beat(2)132187%
Min Revenue beat(2)90485.5%
Max Revenue beat(2)173888%
Revenue beat(4)4
Avg Revenue beat(4)119617%
Min Revenue beat(4)90485.5%
Max Revenue beat(4)173888%
PT rev (1m)-6.36%
PT rev (3m)-6.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-240.52%
EPS NY rev (1m)8.36%
EPS NY rev (3m)72.62%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.93%
Revenue NY rev (1m)-5.12%
Revenue NY rev (3m)63.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.26
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-7.76
FCFYN/A
OCF(TTM)-6.93
OCFYN/A
SpS16.92
BVpS-7.99
TBVpS-9.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 55.82%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 225.95%
Cap/Sales 4.91%
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.69
Altman-Z -4.17
F-Score2
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)630.35%
Cap/Depr(5y)388.12%
Cap/Sales(3y)7.06%
Cap/Sales(5y)7.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y62.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q108.88%
EPS Next Y81.64%
EPS Next 2Y37.7%
EPS Next 3Y23.93%
EPS Next 5Y17.34%
Revenue growth 1Y23.74%
Revenue growth 3Y373.24%
Revenue growth 5Y129.4%
Revenue growth Q2Q128.28%
Revenue Next Year-32.08%
Revenue Next 2Y-19.78%
Revenue Next 3Y-17.86%
Revenue Next 5Y-5.29%
EBIT growth 1Y56.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.12%
EBIT Next 3Y19.62%
EBIT Next 5YN/A
FCF growth 1Y-223.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.26%
OCF growth 3YN/A
OCF growth 5YN/A